AR083721A1 - CONSTANT DOMAIN IgE PEPTIDE VACCINE (CH) - Google Patents
CONSTANT DOMAIN IgE PEPTIDE VACCINE (CH)Info
- Publication number
- AR083721A1 AR083721A1 ARP110101955A AR083721A1 AR 083721 A1 AR083721 A1 AR 083721A1 AR P110101955 A ARP110101955 A AR P110101955A AR 083721 A1 AR083721 A1 AR 083721A1
- Authority
- AR
- Argentina
- Prior art keywords
- immunogenic
- ige peptide
- compositions
- constant domain
- peptide
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se provee también composiciones que comprenden los inmunógenos y procedimientos para la prevención, tratamiento o alivio de trastornos mediados por IgE. Además procedimientos para la producción de estos medicamentos, composiciones inmunogénicas y composiciones farmacéuticas de los mismos y su uso en medicina.Reivindicación 1: Un inmunógeno caracterizado porque comprende al menos un péptido de IgE antigénico unido a un vehículo inmunogénico, en el que: dicho péptido de lgE antigénico consiste en una secuencia de aminoácidos seleccionada del grupo que consiste en las SEC ID Nº 1 a 430; dicho vehículo inmunogénico se selecciona del grupo que consiste en DT (toxina Diftérica), TT (toxoide tetánico) o fragmento C de TT, PD (proteína D de Haemophilus influenzae), CRM197, CRM176, CRM228, CRM45, CRM9, CRM102, CRM103 y CRM107 y en el que dicho péptido de IgE antigénico está entrecruzado químicamente con dicho vehículo inmunogénico.Compositions comprising immunogens and procedures for the prevention, treatment or relief of IgE-mediated disorders are also provided. In addition, procedures for the production of these medicaments, immunogenic compositions and pharmaceutical compositions thereof and their use in medicine. Claim 1: An immunogen characterized in that it comprises at least one antigenic IgE peptide bound to an immunogenic vehicle, wherein: said peptide of antigenic IgE consists of an amino acid sequence selected from the group consisting of SEQ ID NOS 1 to 430; said immunogenic vehicle is selected from the group consisting of DT (Dimeric toxin), TT (tetanus toxoid) or C fragment of TT, PD (Haemophilus influenzae protein D), CRM197, CRM176, CRM228, CRM45, CRM9, CRM102, CRM103 and CRM107 and wherein said antigenic IgE peptide is chemically crosslinked with said immunogenic vehicle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP110101955 AR083721A1 (en) | 2011-06-06 | 2011-06-06 | CONSTANT DOMAIN IgE PEPTIDE VACCINE (CH) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP110101955 AR083721A1 (en) | 2011-06-06 | 2011-06-06 | CONSTANT DOMAIN IgE PEPTIDE VACCINE (CH) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083721A1 true AR083721A1 (en) | 2013-03-20 |
Family
ID=48486020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101955 AR083721A1 (en) | 2011-06-06 | 2011-06-06 | CONSTANT DOMAIN IgE PEPTIDE VACCINE (CH) |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR083721A1 (en) |
-
2011
- 2011-06-06 AR ARP110101955 patent/AR083721A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107020A2 (en) | PCSK9 VACCINE (SUBTILISINE-KEXINA TYPE 9 CONVERTASE PROTEIN) | |
| AR035586A1 (en) | COMPOSITION OF VACCINE, EQUIPMENT, METHODS TO INCREASE THE IMMUNE RESPONSE, USE OF A DERIVATIVE OF 1H-IMIDAZO (4,5-C) QUINOLIN-4-AMINA IN THE MANUFACTURE OF A MEDICINAL PRODUCT, AND COMBINATION OF COMPONENTS FOR SEPARATE, SEQUENTIAL ADMINISTRATION OR CONCOMITANT FOR USE IN DNA VACCINATION | |
| AR078085A1 (en) | ANTIGENIC TAU PEPTIDES AND USES OF THE SAME | |
| MX2011006077A (en) | IgE CH3 PEPTIDE VACCINE. | |
| NO20015073D0 (en) | vaccinations | |
| ATE535252T1 (en) | PEPTIDE CONJUGATE COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ALZHEIMER'S DISEASE | |
| CY1118801T1 (en) | Peptides, Coupling Products and Method for Increasing Immunogenicity of a Vaccine | |
| EA201100586A1 (en) | NEW IMMUNOTHERAPY AGAINST SEVERAL TUMOR TYPES, INCLUDING NEURAL TUMORS AND BRAIN TUMORS | |
| WO2009060281A3 (en) | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | |
| DK2280721T3 (en) | Indoleamin-2,3-dioxygenase-based immunotherapy | |
| EA201071297A1 (en) | NEW AND EFFECTIVE PEPTIDES OF THE MHC II CLASS RECEIVED FROM Survivin | |
| ATE437633T2 (en) | IMMUNOGENIC COMPOSITIONS BASED ON BIODEGRADABLE MICROPARTICLES CONTAINING A DIPHTHERIA AND A TETANUST OXOID | |
| BR112019001656A2 (en) | composition, pharmaceutical composition, vaccine, method for inducing antibodies in an individual, method for treating cancer in a patient in need thereof and method for inducing or ameliorating the immune reaction in an individual in need thereof | |
| EP2942061A3 (en) | Ige ch3 peptide vaccine | |
| BR112017005120A2 (en) | composition, isolated therapeutic conjugate, method for treating cancer in a patient in need thereof, method for inducing antibodies in an individual, pharmaceutical composition and method for inducing antibodies in an individual | |
| RU2014127714A (en) | TOXIN VACCINE Clostridium difficile | |
| AR036315A1 (en) | VACCINE FOR ATEROSCLEROSIS WITH APOCIII FRAGMENTS, ANTI APOCIII ANTIBODIES | |
| DE60331412D1 (en) | HIV vaccine and method of administration | |
| RU2018120009A (en) | METHOD OF VACCINATION AGAINST AUTOANTIGEN IN HUMAN PATIENT | |
| AR041086A1 (en) | VACCINE | |
| AR083721A1 (en) | CONSTANT DOMAIN IgE PEPTIDE VACCINE (CH) | |
| DK1742656T3 (en) | Hitherto unknown peanut skin extract as adjuvant vaccine | |
| Johnston et al. | Transcutaneous delivery of tetanus toxin Hc fragment induces superior tetanus toxin neutralizing antibody response compared to tetanus toxoid | |
| RU2016100235A (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING GPG OLIGODESOXINUCLEOTIDE AND CYCLIC DI-GMF | |
| Zadeh et al. | EVALUATION OF INDUCED ANTIBODIES BY MICROPARTICLES CONTAINING CONJUGATED DETOXIFIED LPS FROM SALMONELLA PARATYPHI C TO TETANUS TOXOID |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |